BIIB vs BMY: Side-by-Side Comparison
Compare Biogen Inc (BIIB) and Bristol-Myers Squibb Company (BMY) side by side: market cap USD 31.91B vs USD 118.71B, P/E 23.2 vs 16.3. Financials, growth and model signals on Bullrun.
| Metric | BIIB | BMY |
|---|---|---|
| Company | Biogen Inc | Bristol-Myers Squibb Company |
| Country / Exchange | United States · NASDAQ | United States · NYSE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-General | Drug Manufacturers-General |
| Market cap | USD 31.91B | USD 118.71B |
| P/E ratio | 23.2 | 16.3 |
| Dividend yield | — | 5.38% |
| Valuation model | 5.7% undervalued | 21.4% undervalued |
| Revenue (FY2025) | USD 9.89B | USD 48.19B |
| Revenue growth YoY | +2.2% | -0.2% |
| Net income | USD 1.29B | USD 7.05B |
| Gross margin | 75.7% | 71.1% |
| Diluted EPS | 8.79 | 3.46 |